Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of the Clever-1 Antibody Bexmarilimab in Combination With Standard of Care Therapy in Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia

Next Previous
X
Search
Trial Profile

A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of the Clever-1 Antibody Bexmarilimab in Combination With Standard of Care Therapy in Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bexmarilimab (Primary) ; Azacitidine; Azacitidine; Venetoclax
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Haematological malignancies; Myelodysplastic syndromes
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms BEXMAB
  • Sponsors Faron Pharmaceuticals

    • Most Recent Events

    • 10 Dec 2024 According to a Faron Pharmaceuticals media release, Faron will host a virtual webinar to discuss the full analysis of data today, 10 December 2024 at 16.00 EET/9am ET/6am PT.
    • 10 Dec 2024 According to a Faron Pharmaceuticals media release, data from this trial presented at the 66th American Society of Hematology (ASH) Annual Meeting
    • 10 Dec 2024 Full analysis of positive phase 2 interim data presented in the Faron Pharmaceuticals Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top